Results of a 1 year randomized open-label multi-centre study of rad versus antilymphocyte globulin(ALG) and azathioprine(AZA) in lung transplant(LT) recipients with bronchiolitis obliterans syndrome(BOS)

2002 ◽  
Vol 21 (1) ◽  
pp. 67
Author(s):  
G.I Snell ◽  
A Frost ◽  
A Glanville ◽  
M.I Hertz ◽  
V.G Valentine ◽  
...  
Keyword(s):  
Bronchiolitis Obliterans ◽  
Lung Transplant ◽  
Bronchiolitis Obliterans Syndrome ◽  
Antilymphocyte Globulin ◽  
Open Label ◽  
Multi Centre Study ◽  
Centre Study

Gastroesophageal Reflux Disease and Idiopathic Lung Fibrosis. From Heartburn to Lung Transplant, and Beyond

2021 ◽  
pp. 000313482199868
Author(s):  
Fernando A. M. Herbella ◽  
Marco G. Patti
Keyword(s):  
Gastroesophageal Reflux Disease ◽  
Gastroesophageal Reflux ◽  
Reflux Disease ◽  
Lung Fibrosis ◽  
Bronchiolitis Obliterans ◽  
Lung Transplant ◽  
Ph Monitoring ◽  
Objective Evaluation ◽  
Bronchiolitis Obliterans Syndrome ◽  
Laparoscopic Operation

Idiopathic pulmonary fibrosis (IPF) and gastroesophageal reflux disease (GERD) are undoubtedly related. Even though it is not clear yet which one is the primary disease, they certainly interact increasing each other’s severity. Symptoms are unreliable to diagnose GERD in patients with IPF, and objective evaluation with pH monitoring and/or bronchoalveolar lavage analysis is mandatory. Pharmacological treatment with proton pump inhibitors (PPIs) may bring control of IPF in few patients, but PPIs do not control reflux but just change the pH of the gastric refluxate. Surgical therapy based on a fundoplication is safe and effective as it controls any type of reflux, independently from the pH of the gastric refluxate. In patients waiting for lung transplantation (if they can tolerate a laparoscopic operation under general anesthesia), a fundoplication before the operation might block the progression of IPF, while after transplantation it might prevent rejection by preventing the bronchiolitis obliterans syndrome.

Survival of lung transplant recipients with bronchiolitis obliterans syndrome

2003 ◽  
Vol 22 (1) ◽  
pp. S193-S194
Author(s):  
V.G Valentine ◽  
M.T Knower ◽  
C Eitmann ◽  
D.M Fuchs ◽  
G.S Dhillon ◽  
...  
Keyword(s):  
Bronchiolitis Obliterans ◽  
Lung Transplant ◽  
Bronchiolitis Obliterans Syndrome ◽  
Transplant Recipients ◽  
Lung Transplant Recipients

414 UPPER ESOPHAGEAL SPHINCTER ABNORMALITIES ARE ASSOCIATED WITH BRONCHIOLITIS OBLITERANS SYNDROME IN LUNG TRANSPLANT PATIENTS

2020 ◽  
Vol 158 (6) ◽  
pp. S-80
Author(s):  
Andrew R. Leopold ◽  
Padma Chamarthy ◽  
Aruj Choudhry ◽  
Alexandra G. Selby ◽  
Emily Friedman ◽  
...  
Keyword(s):  
Bronchiolitis Obliterans ◽  
Lung Transplant ◽  
Bronchiolitis Obliterans Syndrome ◽  
Upper Esophageal Sphincter ◽  
Transplant Patients ◽  
Esophageal Sphincter

scholarly journals Long-term effect of azithromycin in bronchiolitis obliterans syndrome

2019 ◽  
Vol 6 (1) ◽  
pp. e000465
Author(s):  
C.Tji-Joong Gan ◽  
Chris Ward ◽  
Gerard Meachery ◽  
James Laurence Lordan ◽  
Andrew J Fisher ◽  
...  
Keyword(s):  
Overall Survival ◽  
Placebo Group ◽  
Bronchiolitis Obliterans ◽  
Bronchiolitis Obliterans Syndrome ◽  
Term Effect ◽  
Rank Test ◽  
Open Label ◽  
Log Rank Test ◽  
Long Term Effect

IntroductionAzithromycin stabilises and improves lung function forced expiratory volume in one second (FEV1) in lung transplantation patients with bronchiolitis obliterans syndrome (BOS). A post hoc analysis was performed to assess the long-term effect of azithromycin on FEV1, BOS progression and survival .MethodsEligible patients recruited for the initial randomised placebo-controlled trial received open-label azithromycin after 3 months and were followed up until 6 years after inclusion (n=45) to assess FEV1, BOS free progression and overall survival.ResultsFEV1 in the placebo group improved after open-label azithromycin and was comparable with the treatment group by 6 months. FEV1 decreased after 1 and 5 years and was not different between groups. Patients (n=18) with rapid progression of BOS underwent total lymphoid irradiation (TLI). Progression-free survival (log-rank test p=0.40) and overall survival (log-rank test p=0.28) were comparable. Survival of patients with early BOS was similar to late-onset BOS (log-rank test p=0.74).DiscussionLong-term treatment with azithromycin slows down the progression of BOS, although the effect of TLI may affect the observed attenuation of FEV1 decline. BOS progression and long-term survival were not affected by randomisation to the placebo group, given the early cross-over to azithromycin and possibly due to TLI in case of further progression. Performing randomised placebo-controlled trials in lung transplantation patients with BOS with a blinded trial duration is feasible, effective and safe.

Sign in / Sign up

Export Citation Format

Share Document